Verona Pharma plc Pdmr Dealing

 
TIDMVRP 
 
   LONDON, March 20, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that, on March 18, 2019, Mr. Piers 
Morgan, CFO of the Company, purchased 34,481 ordinary shares of 5 pence 
each in the Company (the "Ordinary Shares") at a price of 58 pence per 
Ordinary Share and a total purchase price of GBP19,999.98  Following the 
acquisition, Mr. Morgan will have an interest in the Company of 93,075 
Ordinary Shares, representing 0.09% of the Company's issued share 
capital. 
 
   The purchase by Mr. Morgan follows the purchases made by the Company's 
Chairman, Dr. David Ebsworth, earlier this month totaling approximately 
GBP50,000.00. 
 
   The notification set out below is provided in accordance with the 
requirements of the EU Market Abuse Regulation. 
 
 
 
 
1   Details of the person discharging managerial responsibilities/person 
     closely associated 
    ---------------------------------------------------------------------- 
a)  Name                                     Piers Morgan 
    ---------------------------------------  ----------------------------- 
2   Reason for the notification 
    ---------------------------------------------------------------------- 
a)  Position/status                          Chief Financial Officer 
    ---------------------------------------  ----------------------------- 
b)  Initial notification/Amendment           Initial notification 
    ---------------------------------------  ----------------------------- 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    ---------------------------------------------------------------------- 
a)  Name                                     Verona Pharma plc 
    ---------------------------------------  ----------------------------- 
b)  LEI                                      213800EVI6O6J3TIAL06 
    ---------------------------------------  ----------------------------- 
 
 
 
 
 
 
 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
    ---------------------------------------------------------------------------------------------- 
a)  Description of the financial instrument, type of instrument  Ordinary Shares of 5 pence each 
     Identification code                                          GB00BYW2KH80 
    -----------------------------------------------------------  --------------------------------- 
b)  Nature of the transaction                                    Piers Morgan purchased Ordinary 
                                                                 Shares 
    -----------------------------------------------------------  --------------------------------- 
c)  Price(s) and volume(s)                                       Price(s)   Volume(s) 
                                                                 ---------  ---------------------- 
                                                                 58 pence   34,481 Ordinary Shares 
                                                                 per 
                                                                 Ordinary 
                                                                 Share 
    -----------------------------------------------------------  ---------  ---------------------- 
d)  Aggregated information                                       N/A 
     - Aggregated volume 
     - Price 
    -----------------------------------------------------------  --------------------------------- 
e)  Date of the transaction                                      18 March 2019 
    -----------------------------------------------------------  --------------------------------- 
f)  Place of the transaction                                     London Stock Exchange, AIM 
    -----------------------------------------------------------  --------------------------------- 
 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
 Victoria Stewart, Director of Communications 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: [phone] 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison 
 
 
 
 
 
 
 

(END) Dow Jones Newswires

March 20, 2019 03:00 ET (07:00 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.